Earlier this week, in the southern metropolis of Shenzhen in Guangdong province, French pharmaceutical giant Sanofi signed a letter of intent for cooperation with the government of Shenzhen's Pingshan district.

The two sides agreed to accelerate the market access to innovative vaccines and promote innovative development of the biopharmaceutical industry in the Guangdong-Hong Kong-Macao Greater Bay Area.

Thomas Triomphe, executive vice president and head of vaccines at Sanofi, said the company is currently committed to promoting the landing of several innovative product pipelines in China.

A bio-industry cluster has formed in Pingshan district over recent years. Data showed that by 2022, the number of biopharmaceutical enterprises in Pingshan had exceeded 1,000.

"Sanofi's steady growth in China, especially in vaccines, owes much to the open international business environment created by the Shenzhen municipal government and Pingshan district," said Triomphe.

He added the company would introduce more innovative products and preventive solutions to help support China's public health system and contribute to Shenzhen and the Greater Bay Area's economic growth.